The 5-year survival rate was superior with pembrolizumab.
Cemiplimab monotherapy improved OS and PFS compared with chemotherapy in patients with advanced NSCLC with PD-L1 of at least 50%.
The median duration of response was 11.1 months.
Targeted therapy was associated with better survival with both ctDNA and tissue-only matched patients.
Results from the BOOSTER trial add to data suggesting no benefit with osimertinib in combination over osimertinib alone.
A detailed smoking history may help to inform patient outcomes.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.
A practice improvement project increased lung cancer screening rates among eligible Medicaid recipients in a rural primary care practice in North Carolina.
Responses were observed across EGFR TKI resistance mechanisms.
Efficacy differed by cancer type and KRAS status.
To date, Teva has not received any further complaints or adverse events reports related to this recall.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Patients who underwent CT screening had a lower risk of brain metastasis than patients whose cancer was detected via other methods.
The FDA has approved Lumakras (sotorasib) for KRAS G12C-mutated locally advanced or metastatic NSCLC after at least 1 prior systemic therapy.
Researchers sought to determine the effect this regimen on outcomes for patients with early-stage non-small cell lung cancer.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.
The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.